---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000053"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-08-04T20:10:16+00:00"
generated_at: "2026-08-04T20:11:11.814947+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q2 net product sales $67M (+14% YoY); raises 2026 revenue guidance to $285-295M; in-licenses VEPPANU

## Summary
- Q2 2026 total revenues $78.7M, net income $17.3M ($0.88 diluted EPS); prior year net income $59.6M included $40M non-cash Lilly revenue.
- TAVALISSE sales $47.4M (+18% YoY), REZLIDHIA $8.9M (+27%), GAVRETO $10.7M (-10%).
- In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer for $70M upfront; U.S. launch expected mid-August 2026.
- 2026 revenue guidance raised to $285-295M (ex-VEPPANU) from $275-290M; contract revenue guidance increased to ~$30M.
- Cash & investments $95.3M at June 30, 2026, down from $155.0M at Dec 31, 2025 due to VEPPANU upfront payment.

## SEC filing metadata
- accession: 0001034842-26-000053
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-08-04T20:10:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/0001034842-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000053
- JSON: https://secwatch.observer/filing/0001034842-26-000053.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.